Sumitomo Chemical Company, Limited
Stock Price Chart
2026/03/06 UpdatedPrice Trend
2026/03/06 UpdatedPrice & Trading Details
2026/03/06 UpdatedPRICE
TRADING
Analyst Recommendations 11 analysts
Updated 2026/03/01Shareholder Composition
Updated 2026/03/01Major Holders
Updated 2026/03/01| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
21.6M | -0.37% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
13.7M | +2.62% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
10.1M | 0.00% | |
|
iShares Trust-iShares MSCI EAFE Small-Cap ETF
|
5.6M | 0.00% | |
|
SCHWAB STRATEGIC TRUST-Schwab Fundamental International Equity ETF
|
5.4M | +3.47% | |
|
Fidelity Salem Street TRT-Fidelity SAI Intl Value Index Fd.
|
4.3M | +2.31% |
Dividend History 1Years Growth
Updated 2026/03/01| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥12 | +100.0% |
| 2024 | ¥6 | -50.0% |
| 2023 | ¥12 | -53.8% |
| 2022 | ¥26 | +62.5% |
| 2021 | ¥16 | - |
Financial Performance
2026/03/01 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥2,765,321M | ¥2,895,283M | ¥2,446,893M | ¥2,606,281M |
| Gross Profit | ¥873,863M | ¥820,926M | ¥499,695M | ¥725,476M |
| Operating Income | ¥172,823M | -¥24,187M | -¥431,428M | ¥172,394M |
| Pretax Income | ¥274,197M | ¥39,852M | -¥415,829M | ¥210,683M |
| Net Income | ¥162,130M | ¥6,987M | -¥311,838M | ¥38,591M |
| EPS | ¥99.16 | ¥4.27 | -¥190.69 | ¥23.58 |
| Operating Margin | 6.25% | -0.84% | -17.63% | 6.61% |
| Balance Sheet | ||||
| Total Assets | ¥4,308,151M | ¥4,165,503M | ¥3,934,818M | ¥3,439,784M |
| Total Equity | ¥1,218,101M | ¥1,171,192M | ¥965,753M | ¥900,790M |
| Total Liabilities | ¥3,090,050M | ¥2,994,311M | ¥2,969,065M | ¥2,538,994M |
| Cash | ¥365,429M | ¥305,844M | ¥217,449M | ¥209,838M |
| Interest-bearing Debt | ¥1,350,470M | ¥1,461,366M | ¥1,563,486M | ¥1,286,128M |
| Equity Ratio | 28.27% | 28.12% | 24.54% | 26.19% |
| D/E Ratio | 1.11 | 1.25 | 1.62 | 1.43 |
| Cash Flow | ||||
| Operating CF | ¥171,715M | ¥111,621M | -¥51,317M | - |
| Investing CF | -¥115,421M | -¥19,411M | -¥112,240M | - |
| Financing CF | -¥81,394M | -¥178,502M | ¥49,246M | - |
| Free CF | ¥171,715M | -¥31,960M | -¥204,190M | - |
| Efficiency | ||||
| ROE | 13.31% | 0.60% | -32.29% | 4.28% |
| ROA | 3.76% | 0.17% | -7.93% | 1.12% |
Latest IR Information
-
Notice Regarding Approval for Manufacturing and Marketing of iPS Cell-Derived Product "Amshepli®" for Parkinson's Disease Patients by Our Subsidiary
Sumitomo Pharma, a subsidiary of Sumitomo Chemical, obtained manufacturing and marketing approval on March 6, 2026, for the world's first iPS cell-derived regenerative medicine "Amshepli®". Sales exceeding 100 billion yen are expected in the 2030s.
Read more -
Notice of Registration for Issuance of New Shares by Our Subsidiary
Sumitomo Pharma has completed registration for issuance of up to 60,000,000 shares with a maximum amount of 140 billion yen, planning to promote the growth strategy "Boost 2028" through fundraising.
Read more -
FY2026 Third Quarter Financial Summary [IFRS] (Consolidated)
For the third quarter of FY2026, revenue amounted to JPY 1,706.3 billion (down 10.4% YoY), net income attributable to owners of the parent was JPY 87.4 billion (up 254.2% YoY), the full-year earnings guidance has been revised upward, and the...
Read more -
Notice Regarding Revision of Full-Year Earnings Guidance and Dividend Forecast for the Fiscal Year Ending March 2026
The full-year consolidated earnings guidance for the fiscal year ending March 2026 has been upwardly revised to revenue of 2.3 trillion yen (0.4% increase from previous forecast) and net income attributable to owners of parent of 55 billion yen (22.2%...
Read more
Latest News (5 items)
-
Average Analyst Rating: buy
Average Target Price: ¥574
Rating Score: 2.10 (Based on 11 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Sumitomo Chemical Company, Limited engages in Agro & Life Solutions, ICT & Mobility Solutions, Advanced Medical Solutions, Essential & Green Materials, and Sumitomo Pharma. The Agro & Life Solutions segment offers crop protection chemicals, fertilizers, agricultural materials, household insecticides, products for control of infectious diseases, and feed additives, etc. The ICT & Mobility Solutions segment provides optical products, semiconductor processing materials, compound semiconductor materials, touch screen sensor panels, high-purity aluminum and alumina, specialty chemicals, additives, engineering plastics, and battery materials, etc. The Advanced Medical Solutions segment offers contract development and manufacturing organization business for small-molecule active ingredients and intermediates, oligonucleic acid drug substances, and regenerative medicine, and cell therapy products, etc. The Essential & Green Materials segment offers synthetic resins, raw materials for synthetic fibers, various industrial chemicals, methyl methacrylate products, synthetic resin processed products, industrial aluminum and alumina, and synthetic rubber, etc. The Sumitomo Pharma segment offers small molecule pharmaceuticals. Additionally, the company engages in the manufacture and sale of positive electrode materials for rechargeable batteries. Sumitomo Chemical Company, Limited was founded in 1913 and is headquartered in Tokyo, Japan.
